Next Article in Journal
Molecular Mechanisms of Retinoid Receptors in Diabetes-Induced Cardiac Remodeling
Next Article in Special Issue
Fetal Cell Based Prenatal Diagnosis: Perspectives on the Present and Future
Previous Article in Journal
Prevention of Bone Metastases in Breast Cancer Patients. Therapeutic Perspectives
Previous Article in Special Issue
Prenatal Screening Using Maternal Markers
Article Menu

Export Article

Open AccessReview
J. Clin. Med. 2014, 3(2), 537-565; doi:10.3390/jcm3020537

Non-Invasive Prenatal Testing Using Cell Free DNA in Maternal Plasma: Recent Developments and Future Prospects

Department of Genetics and Developmental Biology, Human Genetics Laboratory, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030-3808, USA
Received: 20 February 2014 / Revised: 11 April 2014 / Accepted: 14 April 2014 / Published: 21 May 2014
(This article belongs to the Special Issue Prenatal Genetic Screening and Diagnosis-Part 1)
View Full-Text   |   Download PDF [306 KB, uploaded 21 May 2014]   |  

Abstract

Recent advances in molecular genetic technologies have facilitated non-invasive prenatal testing (NIPT) through the analysis of cell-free fetal DNA in maternal plasma. NIPT can be used to identify monogenic disorders including the identification of autosomal recessive disorders where the maternally inherited mutation needs to be identified in the presence of an excess of maternal DNA that contains the same mutation. In the future, simultaneous screening for multiple monogenic disorders is anticipated. Several NIPT methods have been developed to screen for trisomy. These have been shown to be effective for fetal trisomy 21, 18 and 13. Although the testing has been extended to sex chromosome aneuploidy, robust estimates of the efficacy are not yet available and maternal mosaicism for gain or loss of an X-chromosome needs to be considered. Using methods based on the analysis of single nucleotide polymorphisms, diandric triploidy can be identified. NIPT is being developed to identify a number of microdeletion syndromes including α-globin gene deletion. NIPT is a profoundly important development in prenatal care that is substantially advancing the individual patient and public health benefits achieved through conventional prenatal screening and diagnosis. View Full-Text
Keywords: prenatal screening; prenatal diagnosis; non-invasive prenatal testing; cell-free DNA; aneuploidy; monogenic disorders; sequencing; Down syndrome; sex chromosome abnormalities prenatal screening; prenatal diagnosis; non-invasive prenatal testing; cell-free DNA; aneuploidy; monogenic disorders; sequencing; Down syndrome; sex chromosome abnormalities
Figures

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Benn, P. Non-Invasive Prenatal Testing Using Cell Free DNA in Maternal Plasma: Recent Developments and Future Prospects. J. Clin. Med. 2014, 3, 537-565.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
J. Clin. Med. EISSN 2077-0383 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top